UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 11, 2019
Supernus Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
Incorporation)
001-35518 | 20-2590184 | |
(Commission File Number) | (IRS Employer Identification No.) | |
1550 East Gude Drive, Rockville MD | 20850 | |
(Address of principal executive offices) | (Zip Code) | |
Registrant’s telephone number, including area code: (301) 838-2500
Not Applicable
(Former name or former address, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Exchange Act
Title of each class | Trading Symbol | Name of each exchange on which registered |
Common Stock, $0.001 par value per share | SUPN | The Nasdaq Global Market |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 11, 2019, Supernus Pharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). The definitive proxy statement pertaining to the Annual Meeting was previously filed by the Company with the Securities and Exchange Commission on April 29, 2019. As of the close of business on April 12, 2019, there were 52,374,248 shares of common stock outstanding and entitled to vote. The tabulation of votes for each proposal voted on by the stockholders was as follows:
Proposal 1: Election of Class I Directors, each to serve until the Annual Meeting of the Company in 2022.
Name | Votes For | Votes Withheld | Broker Non-Votes | |||
Carrolee Barlow, M.D., Ph.D. | 37,325,659 | 5,170,705 | 5,113,461 | |||
Jack A. Khattar | 41,891,684 | 604,680 | 5,113,461 | |||
Proposal 2: Ratification of the appointment of KPMG LLP as the Company’s independent public accounting firm for the fiscal year ending December 31, 2019.
Votes For | Votes Against | Abstain | Broker Non-Votes | |||
47,518,742 | 63,115 | 27,968 | 0 | |||
Proposal 3: To approve, on a non-binding basis, the compensation paid to our named executive officers.
Votes For | Votes Against | Abstain | Broker Non-Votes | |||
40,819,393 | 1,571,092 | 105,879 | 5,113,461 | |||
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SUPERNUS PHARMACEUTICALS, INC. | ||
DATED: June 12, 2019 | By: | /s/ Gregory S. Patrick |
Gregory S. Patrick | ||
Senior Vice-President and Chief Financial Officer | ||
3